Sedation (Central Nervous System) - Drugs in Development, 2021

March 2021 | 64 pages | ID: SA0C906E8338EN
Global Markets Direct

Abstracts

Sedation (Central Nervous System) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sedation - Drugs in Development, 2021, provides an overview of the Sedation (Central Nervous System) pipeline landscape.

Sedation is the depression of irritability or agitation. Symptoms include talk slowly and may slur their speech, unable to concentrate, feel dizzy, slow breathing, heart rate, blood pressure will be lower. Treatment includes barbiturates and benzodiazepines.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sedation - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Sedation (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sedation (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Sedation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Sedation (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Sedation (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Sedation (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Sedation (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Sedation (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Sedation (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Sedation (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Sedation (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Sedation - Overview
Sedation - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Sedation - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sedation - Companies Involved in Therapeutics Development
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Nhwa Pharmaceutical Co Ltd
Melt Pharmaceuticals Inc
Paion AG
Seropeutics LLC
Sichuan Haisco Pharmaceutical Co Ltd
Sichuan Prime Pharmaceutical Co Ltd
Sedation - Drug Profiles
(ketamine + midazolam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cyclopofol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexmedetomidine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EL-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HR-7056 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remimazolam besylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SERx-480 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GABA-A for Sedation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XK-568b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sedation - Dormant Projects
Sedation - Discontinued Products
Sedation - Product Development Milestones
Featured News & Press Releases
Feb 09, 2021: Melt Pharmaceuticals completes phase 1 study for sublingual, non-opioid pain and sedation drug candidate
Jan 28, 2021: Acacia pharma launches BYFAVO(remimazolam) in the United States for procedural sedation in adults undergoing medical procedures lasting 30 minutes or less
Jan 28, 2021: CHMP recommended granting a marketing authorisation for Byfavo (remimazolam) for procedural sedation
Dec 15, 2020: Acacia Pharma announces amendment of its investment agreement with Cosmo Pharmaceuticals for BYFAVO
Dec 14, 2020: National Food and Drug Administration approves the marketing of cyclopofol injection
Oct 09, 2020: Acacia Pharma completes drawdown from €25 million loan facility from Cosmo Pharmaceuticals to support US launch of BYFAVO
Oct 06, 2020: Acacia Pharma announces BYFAVO (remimazolam), its newly approved product for procedural sedation, clears final hurdle on path to commercial launch in the US
Jul 29, 2020: Melt Pharmaceuticals enters the clinical stage of MELT-100 development
Jul 02, 2020: Acacia Pharma announces US FDA approval of BYFAVO (remimazolam) for injection for the induction and maintenance of procedural sedation
Feb 13, 2019: Melt Pharmaceuticals improves patent estate for sublingual non-opioid pain and sedation formulations
Nov 14, 2017: FDA Considers Current Human Abuse Liability Program with Remimazolam in the U.S. As Sufficient; no Second Intranasal Study Required
Oct 18, 2017: Remimazolam phase III Broncoscopy data to be presented at the Chest Annual Meeting 2017
Sep 28, 2017: European Patent Office Grants Formulation Patent For Remimazolam In The EU
Jun 28, 2017: Paion reports positive headline data in U.S. Phase III trial with Remimazolam for procedural sedation undergoing Bronchoscopy
Mar 28, 2017: Paion successfully completes patient recruitment in U.S. Phase III study with Remimazolam for procedural sedation during Bronchoscopy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Sedation, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Sedation - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
Sedation - Pipeline by Jiangsu Nhwa Pharmaceutical Co Ltd, 2021
Sedation - Pipeline by Melt Pharmaceuticals Inc, 2021
Sedation - Pipeline by Paion AG, 2021
Sedation - Pipeline by Seropeutics LLC, 2021
Sedation - Pipeline by Sichuan Haisco Pharmaceutical Co Ltd, 2021
Sedation - Pipeline by Sichuan Prime Pharmaceutical Co Ltd, 2021
Sedation - Dormant Projects, 2021
Sedation - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Sedation, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Types, 2021